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The engineering of and mastery over biological parts has catalyzed the emergence of synthetic biol-
ogy. This ﬁeld has grown exponentially in the past decade. As increasingly more applications of syn-
thetic biology are pursued, more challenges are encountered, such as delivering genetic material
into cells and optimizing genetic circuits in vivo. An in vitro or cell-free approach to synthetic biol-
ogy simpliﬁes and avoids many of the pitfalls of in vivo synthetic biology. In this review, we describe
some of the innate features that make cell-free systems compelling platforms for synthetic biology
and discuss emerging improvements of cell-free technologies. We also select and highlight recent
and emerging applications of cell-free synthetic biology.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Thanks to the shoulders of many biotechnology giants, we are
now leaving the era of scientiﬁc discovery and entering the era
of scientiﬁc mastery. The development of recombinant DNA tools,
the advent of rapid, inexpensive sequencing technology, and now
the development and stockpiling of BioBricks has endowed bio-
technologists unprecedented speed and power to master the
genetic framework of an organism [1,2]. Indeed, researchers can
completely replace genomes or make site-speciﬁc, rationally
designed genome modiﬁcations in only a few days [3–5]. This mas-
tery has sparked the paradigm changing ﬁeld of synthetic biology.
Synthetic biology (synbio) is considered the engineering disci-
pline of biology and ﬁrst began when humans sought to manipu-
late biology toward a desired product. Modern day synbio has its
roots in the development of recombinant DNA tools and has expo-
nentially grown in the 21st century (Fig. 1). Currently, products of
genetically modiﬁed cells comprise 2% of the US economy
($350Bil USD/year) [6]. Exciting new commercial applications
of engineered synthetic biochemical pathways include economi-
cally produced anti-malarial pharmaceutics, petroleum-like biofu-
els, and insecticides [7,8].Increasingly elegant and powerful tools are being developed to
streamline genetic engineering for synbio applications. Examples
of these tools include MAGE and Cas9-CRISPR technologies for
rapid directed genome editing [3–5], the development of diverse
well-characterized BioBricks (gene parts/circuits) [1], and the
synthesis of entirely synthetic viable genomes [9]. There are, how-
ever, fundamental limitations to an in vivo synbio approach. These
limitations are innate to the living organism that hosts the
synthetic pathway and include:
 Control of the gene circuits and chassis behavior
 Monitoring of synthetic pathway dynamics
 Automation and high-throughput optimization
 Economic expansion into low margin applications
 Efﬁcient and broadly applicable chassis systems
An attractive approach to address these challenges is the
emerging and exponentially growing ﬁeld of cell-free synbio
(CF-synbio) (Fig. 1). CF-synbio uses an in vitro approach to over-
come the inherent limitations of using a living organism. A number
of reviews have recently sought to address the transformative, far-
reaching potential of CF-synbio [10–12]. This review focuses on
how CF-synbio can address the challenges of in vivo-based synbio
listed above. We also describe the impact of CF-synbio on protein
synthesis related applications such as pharmaceutics, biocatalysis,
genetic circuit design, and unnatural amino acid incorporation. The
unique advantages of a CF approach demonstrated in increasingly
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Fig. 1. Publications per annum focused on synthetic biology and cell-free synthetic
biology. Research publications focused on synthetic biology and cell-free synthetic
biology have both grown exponentially during the past decade. Data obtained from
Thomson Reuters Web of Knowledge journal database.
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CF-synbio.
2. Engineering cell-free systems for synthetic biology
The most distinct feature of CF systems is the openness of the
reaction environment. The open access afforded CF allows for pro-
pitious features, such as direct control of regulatory elements,
addition of cofactors and enzymes, and in situ monitoring. Further
beneﬁts of CF are real-time control, simpliﬁed metabolic load
balances, reduced toxicity effects. These features make CF a
compelling platform for developing synbio applications.
2.1. Control
A functional synthetic pathway is dependent on appropriate
gene circuit design. In vivo systems must achieve metabolic load
balance to avoid cytotoxicity, maintain cell growth, and optimize
product yields. The ability to appropriately regulate genetic circuits
in vivo is impeded by our limited ability to predict the behavior,
kinetics, and interactions of these circuits [6,11]. More speciﬁcally,
variability of gene expression is introduced by each of the individ-
ual gene parts, such as promoters, ribosome binding sites, gene
sequence, and vector origin of replications; all of which can impact
expression levels in ambiguous manners [14]. Optimizing syn-
thetic pathways is further complicated by idiosyncratic and often
cumbersome gene delivery methods [6]. These impediments add
time, expense, and complexity to creating and optimizing viable
synthetic pathways; as illustrated by Jay Keasling Group’s triumph
to synthetically produce artimisenen in yeast, which took an
estimated 150 person-years to achieve [7].
As synthetic pathways become more complex, the need to pre-
dict the behavior of individual circuits and elements increases.
Although there have been strides in recent years towards improv-
ing predictive analysis, state of the art remains insufﬁcient to
accurately predict the behavior of all genetic elements in concert.
CF-synbio is capable of simplifying and avoiding many of these
issues and may be key to unlocking their secrets for future synbio
applications.
2.1.1. Gene regulation
Although gene expression remains subject to variability from its
genetic elements, CF-synbio systems can overcome the challenge
of controlling gene expression levels by allowing the user to
directly manipulate gene template concentration. Expressionlevels are positively correlated with template concentration
[15,16]. Furthermore, precise control can be directly exerted over
the level of RNA polymerases and even ribosome content [17,18].
Therefore, in CF-synbio, gene design can be simpliﬁed to a single
cassette type (e.g. – T7 promoter/terminator), allowing for high-
throughput optimization of enzyme and cofactor balances [19].
Recent potent examples of facile control through template concen-
tration include optimizing synthetic tRNA content [15,20], balanc-
ing protein expression for multi-protein assemblies [16,21,22],
chaperone protein content [23–25], coexpressed immunosorbance
assays [26], and in vitro reconstitution of eukaryotic translation
factors [27].
A further concern of effective synbio design is the characteriza-
tion of individual regulatory elements. The capacity to directly con-
trol gene content in CF-synbio systems also makes them ideal
chassis for identifying the individual regulatory effects. CF permits
rapid prototyping of regulatory elements, in some cases reducing
characterization time more than 5-fold over in vivo [28,29].
Coexpressing multiple elements in CF-synbio provides ﬁner insight
of direct interactions while reducing the impacts of metabolic load
imbalances or uncharacterized interactions that burden in vivo
analysis [20,30,31]. The potential to more accurately characterize
regulatory elements lays a foundation for more accurate modeling
and design of gene circuits [32–35]. Increased comprehensive
knowledge of circuit parts provides details essential for more
accurate computer aided design (CAD), a much needed tool for
the synbio community [7].
2.1.2. Chassis regulation
The intracellular environment of heterologous host chassis
inherently differ from the native environment of the synthetic
parts. Dissimilarities can lead to undesirable consequences such
as inclusion bodies, improperly folded proteins, metabolic load
imbalances, and toxicity to the host chassis [7,36,37]. Therefore,
host organisms may require unique genetic and fermentation
engineering for optimal expression of each synthetic pathway,
adding labor and cost intensive steps to optimization [38].
Just as the open nature of CF systems allow for dexterous
manipulation of the genetic template content, many other aspects
of CF chassis may be freely controlled and optimized. Components
of the CF chassis can be directly added, removed, or inhibited
including nucleic acids, proteins, substrates, cofactors, and chaper-
ones [39–41]. Furthermore, other important features of the reac-
tion environment may be optimized for individual reactions such
as the redox potential and pH [23,42]. The precise and agile control
made possible by CF-synbio reduces or eliminates the need to
engineer a unique chassis for each synthetic pathway [43,44].
Furthermore, CF-synbio may be used to identify and overcome
complicating aspects of a potential chassis before implanting the
synthetic pathway into the host [45].
2.2. Monitor
Rapid in situ monitoring of synthetic pathways is essential for
rapid engineering. Current techniques for real-time in vivo moni-
toring rely heavily on coexpressed ﬂuorescent reporter proteins
with its additional layer of metabolic load and potential unin-
tended interactions [6]. Other monitoring techniques, such as mass
spectrometry or RT-PCR, are insufﬁciently timely to be considered
for rapid or in situmonitoring. In general, in situmonitoring in vivo
has limited value as cells innately impede access to the intracellu-
lar reaction environment, restricting in situ control possibilities to
fermentation condition adjustments.
CF-synbio expands the available tools for in situ monitoring
beyond ﬂuorescent protein expression. Examples include
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One elegant approach made possible by CF was recently demon-
strated by Rendl and coworkers, who employed microﬂuidic reac-
tors with the capability of online real-time sandwich tagging
assays [47]. Similar to in vivo, in situ monitoring of CF systems
relies heavily on spectrophotometry. The development of non-
spectrophotometric monitoring techniques will facilitate more
diverse applications. Nonetheless, monitoring CF-synbio systems
provides the capacity to immediately and directly respond to sys-
tem dynamics, opening the doors for much needed better, rather
than more, design [6]. The combination of real-time monitoring
and real-time control makes it possible for CF-synbio to incorpo-
rate external process control engineering into the systems dynam-
ics [34].
2.3. Automate
The open and modular features of CF-synbio make it a propi-
tious platform for parallel or sequential rapid prototyping. Auto-
mation using liquid handlers has enabled parallel screening of
microliter reactions that produce sufﬁcient yield for miniature bio-
physical assays, reducing production and analysis from days to
hours [48,49]. Recent strides in microﬂuidic technologies provide
ultrahigh-throughput mechanisms using in vitro compartmentali-
zation (IVC). Femtoliter microﬂuidic reactors, such as emulsions
or plugﬂow modes, have been utilized for synthetic cell facsimiles
[50–52], online aptamer assays [47], probing in vitro expression
noise [53], and probing complex genetic circuits at steady state
[34]. IVC reactions have enabled 106 genes to be analyzed with just
150 lL of reagents [54]. Employing IVC, researchers have been able
to analyze up to 2000 individual reactions per second, allowing for
106 genes to be assayed in well under an hour [54]. Using IVC for
accelerated in vitro evolution minimizes or entirely avoids idiosyn-
cratic steps of in vivo systems such as cloning, transformations, and
gene recovery [45,55].
2.4. Economics
CF systems are generally more expensive than in vivo produc-
tion per gram of protein with approximately 50% of the cost of
CF systems associated with the required energy source [40]. CF sys-
tems typically rely on expensive high-energy metabolites (e.g.
phosphoenolpyruvate, creatine phosphate) as the primary energy
source. In contrast, in vivo systems can rely on signiﬁcantly less
expensive and more energy-rich molecules for ATP regeneration
(e.g. glucose, tryptone). Thus, an attractive technology would be
CF energy systems that utilize more energy-rich metabolites.
Considerable strides have been made to improve energy sources
[56–58]. In a notable example, Caschera and Noireaux recently
reported an improved energy system that incorporates maltose
in the metabolic pathway and results in upwards of 2.3 mg per mL
in a simple batch reaction [58]. Increasingly robust and inexpen-
sive energy sources will be essential for CF-synbio research to
realize its full potential.
An emerging beneﬁt of CF-synbio is the movement to reduce
costs involved with analyzing and optimizing synbio. For example,
screening genetic parts using the IVC in lieu of plates can reduce
overall volume required to screen approximately 78000-fold
[54]. For a screen of 106 genes, this would lower the costs of
reagents from $2.4 million USD to about $31 USD. As the reaction
volumes decrease, yields of CF systems have continued to increase.
Continued efforts in cost reduction are being pursued such as the
alternative reaction mode of continuous exchange CF (CECF)
[34,48]. Reducing the costs of CF-synbio will further expand its
utility to diverse low margin applications, such as biofuels and
industrial biocatalysts [59,60].2.5. Efﬁciency
There is rich diversity of CF systems, reaction modes, and
preparation techniques that provide many options for applying
CF-synbio. For example, there have been considerable well-
described iterations towards streamlining preparation of
Escherichia coli-based CF extract in the last 30 years [61,62]. Some
preparations also facilitate special applications, such as S150
extracts that are free of ribosomes [17]. A lingering difﬁculty of
preparing extracts is consistency of extract viability, which can
be affected by cell growth rate, harvest time, gene content, media
composition, and growth temperature. We have made recent steps
towards optimizing these variables on individual systems, yet gen-
eral fundamental understanding of the impacts of these variables is
not fully characterized [24].
Myriad CF platforms have been reported based on various
organisms (e.g. E. coli, Spodoptera frugiperda) and various strains
of given organisms (e.g. E. coli K12, E. coli BL21). Platforms are
being continually developed such as recently developed platforms
from Saccharomyces cerevisiae [29,62] and human hybridomas [63].
Unfortunately, only a limited subset of the platforms reported in
literature are commercially available. However, with continued
development these diverse platforms will provide a greater variety
of chassis to select from in the future and may further streamline
optimization of a CF-synbio system.
The open nature of CF allows users to employ the most efﬁcient
mode of reaction, whether it be batch, semi-batch, continuous
exchange or continuous stirred tank reactors [64,65]. Unlike
in vivo systems that are generally conﬁned to the cell, CF-synbio
reactors can be optimized for each synthetic pathway. Using reac-
tor design, CF-synbio reactors can be aligned in sequence or paral-
lel [52], perform coupled and uncoupled reactions [66], and be of
any size and shape for optimal performance [52,67,68]. Indeed,
reactor design principles can be directly applied to CF-synbio reac-
tor engineering. Toward this end, CF-synbio reactors have already
been successfully scaled up to 100 L [69] and the components nec-
essary for CF-synbio reactions can be stabilized for long-term stor-
age and stockpiling [70].
3. Emerging applications of cell-free synthetic biology
Although CF-synbio is a newly emerging ﬁeld, its utility has
already been demonstrated for a number of diverse and exciting
applications, as detailed in previous reviews [12,13,71,72]. Below,
we highlight a sampling of recent applications of CF-synbio for pro-
tein production (Fig. 2).
3.1. Pharmaceuticals: antibodies
CF-synbio systems have been demonstrated to be advantageous
for antibody production. For example, in the production of anti-
HER2 antibodies and antibody fragments, molecular chaperones
(yeast and E. coli protein disulﬁde isomerases) were added to facil-
itate active protein production up to 300 mg/L using a prokaryotic
CF system [25]. Furthermore, the direct addition of glutathione
buffers enabled optimization of the redox conditions to facilitate
proper formation of up to 16 disulﬁde bridges per antibody
[25,73,72]. CF-synbio also enables gene expression of multiple
products that can be easily tuned to facilitate proper product inter-
actions. This principle was demonstrated by Yin and coworkers,
where light chains were solely produced for one hour before add-
ing the plasmid to produce complementary heavy chains [25]. This
sequence prevented the aggregation of the heavy chain proteins
that naturally occurs in the absence of sufﬁcient light chain pro-
teins [25]. In addition to prokaryote-based CF systems, eukary-
ote-based systems are also being investigated for the production
DNA
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Fig. 2. Highlighted cell-free-synthetic biology applications in protein synthesis. Illustration of the CF-synbio applications in protein synthesis that are highlighted in this
review. The open environment of CF systems allows for direct addition and optimization of necessary chaperones and cofactors (speciﬁed for each application in the text
above the arrows). DsbC represents the disulﬁde bond isomerase from E. coli. DsbC can be optimally coexpressed or exogenously added to CF-synbio reactions to facilitate the
proper formation of disulﬁde bridges in antibodies. GSSG represents oxidizing glutathione buffers to the control redox potential. HydE, F, G represents the molecular
chaperones required for proper assembly of [FeFe]-hydrogenases. These chaperones can be optimally coexpressed or exogenously added to CF-synbio reactions to produce
the di-iron catalytic core. Transcription Factor represents an input to initiate a genetic circuit or oscillator. For CF-synbio, these can be exogenously added or coexpressed in
the reaction. The open nature of the system allows for virtually instantaneous induction or inhibition of transcription factors, allowing for improved characterization of
individual and complex genetic elements. tRNA/aaRS represents the orthogonal tRNA and aminoacyl-tRNA synthetase pairs required for site-speciﬁc incorporation of
unnatural amino acids (uAAs). These tRNA/aaRS pairs can be exogenously added or coexpressed with the protein of interest. Additional applications of CF-synbio beyond the
protein-synthesis-focused applications illustrated can be found in other excellent reviews [12,13,71,72].
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reticulum-derived membrane vesicles to facilitate correct folding
and posttranslational modiﬁcations such as glycosylation [74,75].
3.2. Pharmaceuticals: vaccines
Using CF-synbio, the opportunities for vaccine innovations and
development are expanding. The primary advantage of a CF system
is the ease of optimizing both the reaction and the product stability
by adjusting DNA template concentrations and controlling the
redox potential for optimal disulﬁde bond formation [22,76,77].
This control has enabled researchers to rapidly produce personal-
ized vaccines for Lymphoma [76]. Another advantage of the CF sys-
tem is the ability to recombinantly express toxic proteins that
would inhibit in vivo expression [78,16]. This ability is improving
vaccine development capabilities, particularly in malaria research
[78,79]. Malaria research has been greatly hindered by the inability
to produce sufﬁcient protein in vivo due to the high A/T content
within the genes. For example, attempts to recombinantly express
108 malarial proteins in E. coli cells resulted in only 60% being suc-
cessfully produced [79]. A further challenge for in vivo production
is the potential to incorrectly glycosylate the immunogenic pro-
teins, which can promote an incorrect immune response [79].
Using CF-synbio, two different research groups have overcome
these challenges. Doolan and coworkers employed an E. coli-based
CF system supplemented with rare transfer RNAs to facilitate
translation of A/T rich regions, resulting in >90% efﬁciency in
expression of 250 malarial proteins [80]. Tsuboi and coworkers
were able to express 478 of 567 malarial proteins by employing
a wheat germ-based CF system, which avoids glycosylation of the
proteins because it lacks the glycosylate enzyme [79]. These CF-
synbio systems are capable of producing the proteins necessary
for rapid vaccine screening.
Virus-like particles (VLPs) are compelling platforms for vaccines
as they are virus-like while remaining non-infectious and the poly-
valent nature of VLPs increases immunogenicity [81]. While in vivoproduction of VLPs has existed for years, there have remained
obstacles to efﬁcient production such as cytotoxicity and control
over expression of monomer proteins [81].
Using CF-synbio, rapid optimization of more robust and stable
VLPs is possible [82]. For example, CF-synbio has facilitated co-
expression of cytotoxic proteins for VLP formation [79], controlled
disulﬁde bond formation for VLP stabilization [42,83] and con-
trolled uAA incorporation [83]. A particularly well-designed appli-
cation of CF-synbio for vaccine development incorporated uAAs in
bacterial ﬂagellin that were subsequently immobilized on VLPs
[84]. Using the features of CF-synbio, cofactors and reagents were
rapidly optimized to improve CF yields of ﬂagellin from 263 lg/
mL to 336.3 lg/mL, [84]. The VLP-immobilized ﬂagellin exhibited
a 10-fold increase in bioactivity compared to free ﬂagellin, laying
the foundation for a new generation of super-vaccines [84].
3.3. Biocatalysis
Use of CF-synbio in biocatalysis enables production of complex
biocatalysts. For example, [FeFe]-hydrogenases have some of nat-
ure’s fastest hydrogen production rates, but are poisoned by oxy-
gen and require multiple specialized chaperones to assemble and
deliver the [FeFe] biocatalytic core to the hydrogenase protein
[85]. Using CF-synbio, Boyer, Kuchenreuther, and coworkers pro-
duced these hydrogenases in an anaerobic environment and in
the presence of the appropriate molecular chaperones, leading to
successful assembly of the [FeFe]-hydrogenases [85,86]. This tool
provided sufﬁcient insight to decipher assembly mechanisms of
the organometallic biocatalytic core [87,88]. In another example,
researchers have included chaperones to increase production and
appropriate folding more than 5-fold of the industrially relevant
enzyme Candida antartica lipase [24,89].
By mimicking biological pathways, combining portions of dif-
ferent pathways, and controlling the proximity of different
enzymes, CF systems have been used to develop new reaction
pathways which rapidly transfer reactants through an enzymatic
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tion of hydrogen from glucose, a CF synthetic enzyme pathway
allowed for a 3-fold increase above the theoretical maximum pro-
duction in microbes [90].
3.4. Genetic circuits
The development of modular gene circuits is a vital tool in the
synthetic biologist’s toolbox because it allows for quick assembly
and control of novel complex networks [30,91]. Progress has been
made with in vivo circuitry [92–94]; however, in vitro methods
provide unique advantages including (1) control and predictabil-
ity of the reaction environment [95–97], (2) a number of well-
characterized components allowing for expedited prototyping
[91,98], and (3) accessibility to the reaction that makes in vitro
circuits truly modular [91,97–99]. A powerful example of the
beneﬁt of in vitro is the development of a rapid prototyping cycle
that can be performed in a standard business day. This allowed
for the prototyping of a 4 component genetic switch in under
8 h [91].
Taking advantage of the rapid prototyping cycle available from
CF systems, many CF circuits have been engineered including logic
gates, memory elements, and oscillators. Speciﬁcally, researchers
have engineered diverse logical gates including AND, OR, NOR,
XOR, NAND, and NOT [19,30,99,100]; memory elements such as
1-input ‘‘push–push’’ and 2-input switches [35,95,101,102]; and
numerous oscillators [34,98,103]. A particularly attractive applica-
tion of these CF genetic circuits is the engineering of minimalistic
artiﬁcial cells and cell-like microdevices. An impressive example
of this is the demonstration of an oscillator in microemulsion drop-
lets ranging from 33 fL to 16 pL [103]. This small partitioning
induced broad variability in the initial reagent concentrations
within each microemulsion, in effect producing a richly diverse
population of reactions [103]. This induced variability could be
used to produce large data sets in an ultrahigh-throughput manner
for the characterization of non-linear biochemical networks and
parameter estimation for circuit behavior.
3.5. Unnatural amino acid incorporation
Unnatural amino acid (uAA) incorporation is another powerful
synbio tool that allows for unique residue chemistry to be incorpo-
rated into proteins. This technology has myriad promising applica-
tions such as ligand–protein interaction, biotherapeutics, and
biocatalysis [104–106].
There are two predominant approaches to incorporate uAAs.
First, the global residue replacement method utilizes natural
amino acid analogues that are recognized by the native machinery
and replace the natural amino acid counterparts [107]. This
requires an auxotrophic host and is limited to a speciﬁc subset of
uAAs that are sufﬁcient analogs. Second, codon reassignment or
stop-codon suppression methods rely on mutated aminoacyl-tRNA
synthetase/tRNA pairs (aaRS/tRNA) that orthogonally aminoacylate
and deliver uAAs for incorporation [108]. CF-synbio has been suc-
cessfully applied to both approaches. For example, CF global resi-
due replacement eliminates the need for an auxotrophic host and
allows for easy optimization of uAA concentrations to avoid bottle-
necks at the uAA incorporation site [83]. The CF-synbio paradigm
has also provided marked improvements to stop-codon suppres-
sion, including progressively improved yields [109,110], optimiza-
tion of tRNA/aaRS pair and uAA concentrations [15], real-time
measurement of reaction conditions [20], and deprotection of uAAs
in situ [111]. A particularly elegant example of CF-synbio
improving uAA incorporation is the control of orthogonal tRNA
(otRNA) content using coexpression in a CF system [15]. This coex-
pression increased yields by providing higher concentrations ofotRNA while circumventing previous labor-intensive steps of
otRNA expression and puriﬁcation. The simultaneous production
of otRNA also eliminates the need for modiﬁed cell strains for
in vivo production of a particular otRNA and allows for convenient,
rapid incorporation of any uAA with a single standard extract.
This ability to site-speciﬁcally introduce novel chemistry into
proteins using CF-synbio opens up many diverse applications
including controlled drug attachment to antibodies for homoge-
nous production of therapeutics [104], orientation-controlled
covalent immobilization of proteins to non-biological surfaces
[112], functionalized virus-like particles [113], and incorporation
of probes and labels [105,114]. A poignant illustration of the use-
fulness of CF uAA incorporation is the site-speciﬁc incorporation
of PEGylated amino acids into protein therapeutics to prolong sta-
bility, and thus lifetime, in the bloodstream [115].
4. Conclusions
In the biological engineering ﬁeld of synthetic biology, cell-free
systems are emerging as a powerful tool to overcome inherent lim-
itations of living cells. Speciﬁcally, the open nature of CF systems
enables unparalleled control of gene expression, chassis optimiza-
tion, in situ monitoring, and automation. In addition, CF systems
are becoming increasingly attractive for more applications due to
recent developments that reduce the cost and improve the efﬁ-
ciency of CF. Already, CF-synbio has been demonstrated as an
effective tool for the applications of antibody production, vaccine
assembly, gene circuit development, biocatalyst production, and
uAA incorporation. The growing number of applications and innate
advantages discussed above set the stage for an emerging age of
cell-free synthetic biology.
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